Another Wet Age Related Macular Degeneration Drug Approved by FDA

Recommend to others!


It is an undeniable fact that reaching 40 years old and above entails not only physical degeneration but also mental deterioration. It is also an inevitable factor that old age predisposes one in several diseases, the sad part is, and we cannot alter the risks due to this matter since we cannot go through every individual’s ages. Instead, solutions to every ailment, like treatments and preventive measures are the core being focused to.

According to the Macular Degeneration Research, a program of the American Health Assistance Foundation, “macular degeneration causes deterioration of the macula, the central area of the retina. The retina is a paper-thin tissue at the back of the eye where light sensitive cells send visual signals to the brain. Sharp, clear, straight-ahead vision is processed by the macula, and damage to it results in blind spots and blurred or distorted vision. Those affected by macular degeneration find many daily activities such as driving and reading, increasingly difficult. Macular degeneration usually affects individuals older than 50 years of age, and scientific evidence shows that genes may play a role in the development of nearly three out of four cases of this devastating eye disease.”

“Macular degeneration is a major cause of visual impairment in the U.S. It is estimated that as many as 11 million people in the United States have some form of age-related macular degeneration. By 2050, this figure will double to nearly 22 million.”

Regeneron Pharmaceuticals proposed a new drug indicated for Wet Age Related Macular Degeneration called aflibercept (Eylea). Recently, it was then approved by the FDA. The Wet ARMD is one the kinds of ARMD wherein the retinal pigment in the macula starts to deteriorate and new blood vessels start to form.

Unfortunately, the tiny blood vessels are fragile and tend to rapture which releases blood and fluids in the macular part of the retina. This damages the rods and cones that cause loss of vision. On the other hand, Afliberecept, also known as VEGF Trap-Eye, is made up of fragments of human IgG and the VEGF receptor protein and placental growth factor as well as VEGF. Its action is focused on preventing or distorting the blood vessel formed in the case of wet macular degeneration.

The action of the said drug is tantamount to the Ranibizumab (Lucentis), which is a DFA approved drug for wet macular degeneration.  However, it was found out that this medication is contraindicated for patients with intraocular problems or ongoing eye infections. But unlike other VEGF inhibitors, there is a lesser probability for Eylea to cause any embolitic or thrombolytic effect that can lead to stroke or myocardial infarction. Also, further study is proposed to establish for the other beneficial effects of this newly approved drug on tumors that has new blood vessel forming as well. Nevertheless, drug options counts for wet ARMD increases as the Eylea was approved.




Speak Your Mind


Current day month ye@r *